Results 71 to 80 of about 45,090 (245)

RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation

Cancer Science, EarlyView.
RASD2 drives clear cell renal cell carcinoma (ccRCC) progression by physically interacting with RAF1 to induce its Ser338 phosphorylation, which subsequently activates the P38/ERK–MAPK signaling pathway to promote malignant tumor phenotypes and poor prognosis.
Jingxuan Yu, Gang Yu, Yuan Liu, Yu Zhou, Wei Liu, Lin Wang, Lide Liu, Yan Liu, Tiejun Pan, Zhenyu Liu, Lei Gao   +10 more
wiley   +1 more source

Hypertension caused by pheochromocytoma and its treatment

, 2019
A pheochromocytoma a mellékvese velőállományának chromaffin sejtjeiből kifejlődő catecholaminokat termelő, raktározó, szekretáló és metabolizáló, ritka neuroendokrin tumor.
Papp, Ádám
core  

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

European Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

Epidemiologic Profile and Clinical Outcomes of Patients with Pheochromocytoma at the University of the Philippines - Philippine General Hospital (UP-PGH)

Journal of the ASEAN Federation of Endocrine Societies
Objective. This study aims to describe the epidemiologic profile and determine the clinical outcomes of patients with pheochromocytoma at the University of the Philippines Philippine General Hospital (UP-PGH). Methodology.
Edrome Hernandez, Cecilia Jimeno, Elizabeth Paz-Pacheco   +2 more
doaj   +1 more source

Familial nonsyndromic pheochromocytoma.

, 2006
Judging from recent data, heritable forms account for 30-40% of pheochromocytomas. The molecular basis for the familial pheochromocytoma has been largely elucidated and the role of germline mutation of the VHL, RET, SDHB, and SDHD genes has been ...
MIAN, CATERINA, FRANCESCA SCHIAVI, PAOLA DE LAZZARI, SCHIAVI F, CATERINA MIAN, SATTAROVA S, LAURA ZAMBONIN, IACOBONE, MAURIZIO, DE LAZZARI P, MERANTE BOSCHIN, ISABELLA, MURGIA, ALESSANDRA, ALESSANDRA MURGIA, TONIATO, ANTONIO, FAVIA, GENNARO, MAURIZIO IACOBONE, MARIA ROSA PELIZZO, MANTERO, FRANCO, ERLIC Z, SABINA SATTAROVA, ZAMBONIN L, MARTELLA M, FRANCO MANTERO, OPOCHER, GIUSEPPE, GIUSEPPE OPOCHER, ISABELLA MERANTE BOSCHIN, PELIZZO, MARIA ROSA, ANTONIO TONIATO, MADDALENA MARTELLA, GENNARO FAVIA, ZORAN ERLIC   +29 more
core   +1 more source

Adrenocorticotropic Hormone Secreting Pheochromocytoma Underlying Glucocorticoid Induced Pheochromocytoma Crisis [PDF]

, 2018
Context. Pheochromocytomas are hormone secreting tumors of the medulla of the adrenal glands found in 0.1–0.5% of patients with hypertension. The vast majority of pheochromocytomas secrete catecholamines, but they have been occasionally shown to also ...
Matan Fischer, Haggi Mazeh, Gil A. Geva, Iddo Z. Ben-Dov, David J. Gross, Karine Atlan   +5 more
core   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, EarlyView.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Laparoscopic management of recurrent pheochromocytoma: A case report

Journal of Minimal Access Surgery, 2016
Recurrence of pheochromocytoma after a total adrenalectomy is uncommon. Such recurrent tumours are mostly managed by the open technique, with very few studies reporting laparoscopic management.
Harshit Garg, Manpreet Uppal, Sreesanth Kelu Sreedharan, Sandeep Aggarwal   +3 more
doaj   +1 more source

Bariatric Surgery for Pre-Operative Weight Reduction in a Patient with Pheochromocytoma

, 2019
Objective: Obesity is a predictor of adverse outcomes in patients undergoing adrenalectomy. Pre-adrenalectomy weight reduction is becoming an increasingly common challenge in view of the rising prevalence of obesity.
Haigh, Kate J, Davoren, Peter
core   +1 more source

Outcomes and opportunities: evaluating an unselected cohort of patients with adrenal incidentaloma at a tertiary hospital in New Zealand

Internal Medicine Journal, EarlyView.
Abstract Background The prevalence of adrenal incidentalomas is increasing, along with the incidence of functional or malignant lesions. This study assessed how imaging of adrenal incidentalomas at a tertiary hospital in Auckland, New Zealand, without a dedicated adrenal incidentaloma service, conformed to the American College of Radiology (ACR ...
Anthony Benfell, Liam Quinlan, Kunj Joshi, Tej Joshi, Shekhar Sehgal   +4 more
wiley   +1 more source